Security

LLY: Equity Research & Market Analysis

Finvaulta tracks 78 research reports on LLY, updated through August 15, 2026. Latest: “Obesity Tracker: Weekly News Digest and Trial Updates”.

Eli Lilly (LLY) continues to capture significant institutional attention, highlighted by record-breaking clinical data for its weight loss candidate, retatrutide. The company remains a focal point in high-conviction investment strategies like the J.P. Morgan Analyst Focus List, which emphasizes top-tier growth and performance relative to the S&P 500. Beyond its metabolic portfolio, LLY is strategically positioned within the "Longevity" investment theme, as seniors emerge as a powerful economic force driving demand for vitality-focused healthcare and wellness. While the broader biopharma sector sees a shift toward the IL-23 class in immunology, analysts maintain a pro-risk stance on high-performing U.S. equities like LLY despite moderated global growth forecasts of 2.6%. This outlook is supported by robust 2026 growth expectations for technology and healthcare sectors that demonstrate strong innovation and successful trial outcomes. Ultimately, LLY’s trajectory is framed by its leadership in the obesity market and its alignment with long-term demographic shifts toward healthy aging.

Featured reports

Obesity Tracker: Weekly News Digest and Trial Updates

Jefferies·Aug 15, 2026

Jefferies' weekly obesity tracker highlights Lilly's legal escalation against illicit retatrutide marketing ahead of an early 2027 filing target, United Biotech's active IND for oral small-molecule GLP-1 candidate UBT48128, and Ascletis advancing its amylin and GLP-1/GIP combination programs into Phase 1.

Eli Lilly & Co. Commercial Momentum Uninterrupted

Goldman Sachs·Aug 6, 2026

Eli Lilly delivered a strong 2Q26 performance driven by volume growth in its incretin portfolio and early success from the Medicare obesity coverage unlock. Goldman Sachs raised the 12-month price target to $1,367, citing upward sales revisions and momentum in the non-incretin business.

Eli Lilly & Co. Earnings First Take

Goldman Sachs·Aug 5, 2026

Eli Lilly (LLY) delivered a strong 2Q26 beat on both revenue and profit, driven by its flagship incretin products Mounjaro and Zepbound. The company significantly raised its full-year 2026 revenue guidance by $2.5bn at the midpoint.

Equity Thematic Strategy

J.P. Morgan·Jul 28, 2026

Healthcare offers a rare combination of durable growth, attractive relative valuation, and accelerating earnings potential for 2027. It remains under-owned and is positioned to benefit as investors seek to diversify away from crowded AI themes.

Global Healthcare: Pharmaceuticals Friday Fodder: Narratives Into 2Q26 Earnings

Goldman Sachs·Jul 10, 2026

This report previews the 2Q26 earnings season for Large Cap Biopharma, noting the influence of macro-driven sector rotations and increased market sensitivity to clinical readouts following recent trial failures.

Longevity Weekly Pulse

UBS·Jul 8, 2026

This report provides a preview of 2Q26 health care earnings, highlighting the market focus on GLP-1 drug performance, medical device sector trends, and pivotal pharmaceutical pipeline catalysts.

Americas Morning Research Summary

Barclays·Jun 10, 2026

This report provides a summary of Barclays Equity Research publications for June 10, 2026, covering various sectors including consumer goods, technology, healthcare, and financials.

European Morning Research Summary

Barclays·May 11, 2026

Barclays' morning research summary highlights a return to volume growth in consumer staples and tracks 1Q26 earnings results across European banks, energy, and healthcare. Key themes include rising US gasoline prices, electrification re-ratings, and significant hyperscaler capex growth projections for 2026.

Longevity Weekly Pulse: Strong 1H26 Results from WuXi Biologics and Innovent

UBS·Sep 2, 2026

BioArctic: 2Q26 Update: Exidavnemab Progressed to Phase 2b; Limited Updates on Collaboration Deals

Goldman Sachs·Aug 27, 2026

Longevity Weekly Pulse #70: GLP-1 Prescription Volumes Gain Momentum

UBS·Aug 26, 2026

All reports

Page 1 of 4

Use in AI assistants

Search this research archive inside ChatGPT, Claude, or Perplexity.

ChatGPT Claude Perplexity

Health Care Societal Shifts Intelligence Equities NVO Barclays Industrials

Get full access

Create an account to follow this research